AZD9291 US Expanded Access Program

Study of AZD9291 in NSCLC Patients Harboring T790M Mutation Who Failed EGFR TKI and With Brain and/or LMS

NCT03257124 ·Status: UNKNOWN ·Phase: PHASE2

AZD9291 First Time In Patients Ascending Dose Study

NCT01802632 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

AZD9291, an Irreversible EGFR-TKI, in Relapsed EGFR-mutated Non-small Cell Lung Cancer Patients Previously Treated With an EGFR-TKI, Coupled to Extensive Translational Studies

NCT02504346 ·Status: UNKNOWN ·Phase: PHASE2

An Observational Study to Evaluate AZD9291 Treatment in Patients With T790M Positive Non-small Cell Lung Cancer

NCT03457220 ·Status: COMPLETED

Study of AZD9291 Plus MEDI4736 Versus AZD9291 Monotherapy in NSCLC After Previous EGFR TKI Therapy in T790M Mutation Positive Tumours

NCT02454933 ·Status: COMPLETED ·Phase: PHASE3

Phase II Single Arm Study of AZD9291 to Treat NSCLC Patients in Asia Pacific

NCT02442349 ·Status: COMPLETED ·Phase: PHASE2

AZD9291 in Combination With Ascending Doses of Novel Therapeutics

NCT02143466 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung Cancer

NCT02228369 ·Status: COMPLETED ·Phase: PHASE1

Uncommon EGFR AZD9291

NCT03424759 ·Status: UNKNOWN ·Phase: PHASE2

Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010MA in Advanced Non Small Cell Lung Cancer

NCT02448251 ·Status: TERMINATED ·Phase: PHASE1

Osimertinib (AZD9291) in First-line Locally Advanced or Metastatic NSCLC Patients With EGFR and EGFR T790M

NCT02841579 ·Status: COMPLETED ·Phase: PHASE2

AZD9291 (Osimertinib) Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT02151981 ·Status: COMPLETED ·Phase: PHASE3

Study to Assess the Effect of Rifampicin on Blood Levels and Safety of AZD9291, in Patients With EGFRm+ NSCLC

NCT02197247 ·Status: COMPLETED ·Phase: PHASE1

Expanded Access to Telisotuzumab Adizutecan

NCT05982873 ·Status: AVAILABLE

Open Label, Prospective Study to Investigate Efficacy and Safety of AZD9291 in BM From NSCLC Patients With EGFR T790M

NCT02972333 ·Status: UNKNOWN ·Phase: PHASE3

Neo-adjuvant Trial With AZD9291 in EGFRm+ Stage IIIA/B NSCLC

NCT02824952 ·Status: UNKNOWN ·Phase: PHASE2

Docetaxel With or Without FGFR Inhibitor AZD4547 in Treating Patients With Recurrent Non-Small Cell Lung Cancer

NCT01824901 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Erlotinib and AT-101 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations

NCT00988169 ·Status: TERMINATED ·Phase: PHASE2

Liquid Biopsy as a Tool to Evaluate Resistance to First and Third (AZD9291) (EGFR) (TKIs) in (EGFR) Mutant NSCLC

NCT02771314 ·Status: UNKNOWN ·Phase: PHASE2

Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)

NCT06303167 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Frequency of EGFR Mutations in Latinos/Hispanics With Non-Small Cell Lung Cancer

NCT01255150 ·Status: COMPLETED

Expanded Access Study of Afatinib in Treatment-naive or Chemotherapy Pre-treated Patients With Non-small Cell Lung Cancer (NSCLC)

NCT01931306 ·Status: APPROVED_FOR_MARKETING

Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)

NCT02157883 ·Status: COMPLETED ·Phase: PHASE1

Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...

NCT01229150 ·Status: COMPLETED ·Phase: PHASE2

Osimertinib in First and Second Line Treatment of NSCLC Harboring EGFR Mutations From Circulating Tumor DNA

NCT02769286 ·Status: COMPLETED ·Phase: PHASE2